Foghorn Therapeutics, Inc. (FHTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Foghorn Therapeutics, Inc. (FHTX)

Company Performance

Current Price

as of Oct 16, 2024

$8.11

P/E Ratio

N/A

Market Cap

$448.72M

Description

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Metrics

Overview

HQCambridge, MA
SectorHealth Technology
IndustryBiotechnology
TickerFHTX
Price$8.11+6.15%

Trading Information

Market Cap$448.72M
Float51.68%
Average Daily Volume (1m)184,300
Average Daily Volume (3m)153,264
EPS-$1.95

Company

Revenue$35.18M
Rev Growth (1yr)23.02%
Net Income-$22.98M
Gross Margin88.39%
EBITDA Margin-340.21%
EBITDA-$23.43M

EV$52.33M
EV/Revenue1.49
P/EN/A
P/S11.89
P/BN/A

Documents

Factset Street Account

Foghorn Therapeutics to present new data at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. ($3.09, 0.00) (2023-10-24T12:08:05Z)

Foghorn Therapeutics reports Q3 EPS ($0.34) vs FactSet ($0.70) [4 est, ($0.85)-(0.55)] ($3.68, 0.00) (2023-11-02T11:23:49Z)